Publications
Filters: First Letter Of Last Name is M [Clear All Filters]
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy." Breast Cancer Res 19, no. 1 (2017): 18.
" Assessing Time-Varying Causal Interactions and Treatment Effects with Applications to Mobile Health., 2016.
On random sample size, ignorability, ancillarity, completeness, separability, and degeneracy: sequential trials, random sample sizes, and missing data." Stat Methods Med Res 23, no. 1 (2014): 11-41.
"SNPpy--database management for SNP data from genome wide association studies." PLoS One 6, no. 10 (2011): e24982.
" Bayesian spatial transformation models with applications in neuroimaging data." Biometrics 69, no. 4 (2013): 1074-83.
"Active Clinical Trials for Personalized Medicine." J Am Stat Assoc 111, no. 514 (2016): 875-887.
"Estimation After a Group Sequential Trial." Stat Biosci 7, no. 2 (2015): 187-205.
"Properties of Estimators in Exponential Family Settings with Observation-based Stopping Rules." J Biom Biostat 7, no. 1 (2016).
"Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint." Stat Med 30, no. 13 (2011): 1502-18.
"Data for cancer comparative effectiveness research: past, present, and future potential." Cancer 118, no. 21 (2012): 5186-97.
"Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: findings from Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION)." Am Heart J 165, no. 2 (2013): 193-9.
"Cancer pharmacogenomics: early promise, but concerted effort needed." Science 339, no. 6127 (2013): 1563-6.
"Localized differences in caudate and hippocampal shape are associated with schizophrenia but not antipsychotic type." Psychiatry Res 211, no. 1 (2013): 1-10.
"Consistency and overfitting of multi-omics methods on experimental data." Brief Bioinform 21, no. 4 (2020): 1277-1284.
"Maximum likelihood estimation in generalized linear models with multiple covariates subject to detection limits." Stat Med 30, no. 20 (2011): 2551-61.
"Gene set analysis methods: a systematic comparison." BioData Min 11 (2018): 8.
"Robust kernel association testing (RobKAT)." Genet Epidemiol 44, no. 3 (2020): 272-282.
" A Fast Multiple-Kernel Method With Applications to Detect Gene-Environment Interaction." Genet Epidemiol 39, no. 6 (2015): 456-68.
"Semiparametric regression for the weighted composite endpoint of recurrent and terminal events." Biostatistics 17, no. 2 (2016): 390-403.
"Efficient Estimation of Semiparametric Transformation Models for the Cumulative Incidence of Competing Risks." J R Stat Soc Series B Stat Methodol 79, no. 2 (2017): 573-587.
"Semiparametric regression analysis of interval-censored competing risks data." Biometrics 73, no. 3 (2017): 857-865.
"Multivariate phenotype association analysis by marker-set kernel machine regression." Genet Epidemiol 36, no. 7 (2012): 686-95.
"Inference on phenotype-specific effects of genes using multivariate kernel machine regression." Genet Epidemiol 42, no. 1 (2018): 64-79.
"Multiplicative rates model for recurrent events in case-cohort studies." Lifetime Data Anal 26, no. 1 (2020): 134-157.
"Drug safety in spontaneous reports, observational databases, and clinical trials: Can we do better?., 2011.
A hybrid Bayesian hierarchical model combining cohort and case-control studies for meta-analysis of diagnostic tests: Accounting for partial verification bias." Stat Methods Med Res 25, no. 6 (2016): 3015-3037.
"Statistical methods for multivariate meta-analysis of diagnostic tests: An overview and tutorial." Stat Methods Med Res 25, no. 4 (2016): 1596-619.
"Incorporating higher-order representative features improves prediction in network-based cancer prognosis analysis." BMC Med Genomics 4 (2011): 5.
"A trivariate meta-analysis of diagnostic studies accounting for prevalence and non-evaluable subjects: re-evaluation of the meta-analysis of coronary CT angiography studies." BMC Med Res Methodol 14 (2014): 128.
"Assessing Similarity to Existing Drugs to Decide Whether to Continue Drug Development." Stat Biopharm Res 4, no. 3 (2012): 293-300.
"